Molina-Andújar Alicia, Alcubilla Pau, Santiago Pedro, Blasco Miquel, Cucchiari David, Piñeiro Gaston, Andrea Rut, Fernández Sara, Reverter Enric, Mercadal Jordi, Quintana Eduard, Poch Esteban
Nephrology and Kidney Transplantation Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Clinical Pharmacology Department, Hospital Clínic, Barcelona, Spain.
J Nephrol. 2021 Feb;34(1):105-112. doi: 10.1007/s40620-020-00760-x. Epub 2020 Jun 3.
Intermittent renal replacement therapy (IRRT) is prescribed across intensive care units (ICU) worldwide. While research regarding the prescribed dialysis dose has not yielded results concerning mortality, it is still unknown whether the same applies to the actual delivered dose.
We retrospectively analyzed two different cohorts of patients (562 IRRT sessions) who were admitted to the intensive care units at Hospital Clínic of Barcelona and required renal replacement therapy with IRRT. The first cohort included patients with acute kidney injury (AKI) (n = 42) and the second included patients already on chronic hemodialysis (CKD 5D) (n = 47). Only patients who had at least 3 recorded hemodialysis sessions in the ICU and with no previous continuous renal replacement therapy (CRRT) were included. The achieved dose was measured as Kt (L) by ionic dialysance and the primary endpoint was 90-day mortality.
Ninety-day mortality was 40.5% (n = 17) in the AKI cohort and 23.9% (n = 11) in the CKD 5D cohort with mean Kt of 43 ± 8.27 L and 47 ± 9.65 L respectively. Kt dose of IRRT was associated with 90-day mortality in the AKI cohort in a multivariate surveillance analysis adjusted for confounding factors (HR 0.935 [0.88-0.99], p = 0.02). Only the Kt dose and age remained statistically associated with the outcome in the AKI cohort.
Delivered dialysis dose as measured by ionic-dialysance Kt may be associated with survival in critically-ill patients with AKI, while it does not seem to affect outcomes in critically-ill CKD 5D patients. This exploratory analysis will need confirmation in larger prospective studies.
间歇性肾脏替代治疗(IRRT)在全球范围内的重症监护病房(ICU)中均有应用。虽然关于规定透析剂量的研究尚未得出与死亡率相关的结果,但实际给予的剂量是否同样如此仍不清楚。
我们回顾性分析了巴塞罗那临床医院重症监护病房收治的两个不同队列的患者(562次IRRT治疗),这些患者需要接受IRRT进行肾脏替代治疗。第一个队列包括急性肾损伤(AKI)患者(n = 42),第二个队列包括已接受慢性血液透析(CKD 5D)的患者(n = 47)。仅纳入在ICU至少有3次记录的血液透析治疗且此前未接受过连续性肾脏替代治疗(CRRT)的患者。通过离子透析测定达到的剂量为Kt(L),主要终点为90天死亡率。
AKI队列的90天死亡率为40.5%(n = 17),CKD 5D队列的为23.9%(n = 11),平均Kt分别为43±8.27 L和47±9.65 L。在针对混杂因素进行调整的多变量监测分析中,IRRT的Kt剂量与AKI队列的90天死亡率相关(风险比0.935 [0.88 - 0.99],p = 0.0